Nuwellis (NUWE) to Release Earnings on Tuesday

Nuwellis (NASDAQ:NUWE) is expected to release its Q4 2025 results before the market opens on Tuesday, March 10th. Analysts expect Nuwellis to post earnings of ($1.56) per share and revenue of $2.31 million for the quarter. Investors can find conference call details on the company’s upcoming Q4 2025 earning report page for the latest details on the call scheduled for Tuesday, March 10, 2026 at 9:00 AM ET.

Nuwellis Stock Performance

Shares of NUWE stock opened at $1.43 on Monday. Nuwellis has a 52 week low of $1.40 and a 52 week high of $56.28. The company’s 50 day moving average price is $2.18 and its two-hundred day moving average price is $2.89. The company has a market capitalization of $2.67 million, a P/E ratio of -0.01 and a beta of -0.03.

Wall Street Analyst Weigh In

A number of brokerages recently commented on NUWE. Weiss Ratings restated a “sell (e+)” rating on shares of Nuwellis in a report on Monday, December 29th. Wall Street Zen cut Nuwellis from a “hold” rating to a “sell” rating in a report on Saturday, November 15th. One equities research analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Hold”.

About Nuwellis

Nuwellis (NASDAQ:NUWE) is a medical technology company focused on developing therapies and devices to manage fluid overload in patients with cardiorenal and cardiovascular conditions. The company’s core business revolves around designing, manufacturing and marketing the Aquadex™ FlexFlow® System, a gentle ultrafiltration device intended to remove excess fluid in patients with acute decompensated heart failure, cardiorenal syndrome and other fluid‐overload disorders. By providing an alternative to traditional diuretic therapy, Nuwellis aims to improve patient outcomes and reduce hospital stays.

The Aquadex FlexFlow System operates by drawing blood through a low‐shear filter and returning it to the patient, allowing precise control of fluid removal at the bedside outside of an intensive care setting.